FDA awards Atossa Therapeutics rare pediatric designation for Z-endoxifen milestone

FDA awards Atossa Therapeutics rare pediatric designation for Z-endoxifen milestone
Atossa granted FDA pediatric status

The U.S. Food and Drug Administration has granted Rare Pediatric Disease designation to (Z)-endoxifen for the treatment of McCune-Albright Syndrome, representing a significant regulatory milestone for Atossa Therapeutics.

Atossa Therapeutics said (Z)-endoxifen may address key drivers of the disease and improve patient outcomes. This move highlights the company's ongoing commitment to developing targeted therapies for rare conditions. The designation may provide additional incentives, including a potential priority review voucher if the therapy is approved.

Atossa Therapeutics has previously advanced Z-endoxifen in oncology, reporting key FDA designations and new clinical leadership earlier this year. The company has also explored endoxifen as a novel approach to managing Duchenne muscular dystrophy through recent presentations. These developments support Atossa's focus on expanding the potential uses of its pipeline therapies.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.